相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers
Satoshi Tsunetoh et al.
CANCER BIOLOGY & THERAPY (2010)
Inhibition of Carboplatin-Induced DNA Interstrand Cross-link Repair by Gemcitabine in Patients Receiving these Drugs for Platinum-Resistant Ovarian Cancer
Jonathan A. Ledermann et al.
CLINICAL CANCER RESEARCH (2010)
Clinicopathological characteristics of mucinous adenocarcinoma of the ovary
Muneaki Shimada et al.
GYNECOLOGIC ONCOLOGY (2009)
Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma
Hiroaki Itamochi et al.
CANCER SCIENCE (2008)
Quantifying synergism/antagonism using nonlinear mixed-effects modeling: A simulation study
John C. Boik et al.
STATISTICS IN MEDICINE (2008)
Biweekly gemcitabine and cisplatin in platinum-resistant/refractory, paclitaxel-pretreated, ovarian and peritoneal carcinoma
George Bozas et al.
GYNECOLOGIC ONCOLOGY (2007)
Cisplatin plus gemcitabine in platinum-refractory ovarian or primary peritoneal cancer: A phase II study of the Gynecologic Oncology Group
Cheryl A. Brewer et al.
GYNECOLOGIC ONCOLOGY (2006)
Hypoxia increases resistance of human pancreatic cancer cells to apoptosis induced by gemcitabine
K Yokoi et al.
CLINICAL CANCER RESEARCH (2004)
Inhibition of phosphorylation of a forkhead transcription factor sensitizes human ovarian cancer cells to cisplatin
E Arimoto-Ishida et al.
ENDOCRINOLOGY (2004)
Cisplatin: mode of cytotoxic action and molecular basis of resistance
ZH Siddik
ONCOGENE (2003)
Gemcitabine potentiates cisplatin cytotoxicity and inhibits repair of cisplatin-DNA damage in ovarian cancer cell lines
MA Moufarij et al.
MOLECULAR PHARMACOLOGY (2003)
Gemcitabine reverses cisplatin resistance: Demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma
PG Rose et al.
GYNECOLOGIC ONCOLOGY (2003)
Phase II trial of gemcitabine plus cisplatin repeating doublet therapy in previously treated, relapsed ovarian cancer patients
RA Nagourney et al.
GYNECOLOGIC ONCOLOGY (2003)
Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel
S Mabuchi et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase/Akt pathway
JQ Cheng et al.
DRUG RESISTANCE UPDATES (2002)
分享论文
